Stay updated with breaking news from Advanced Breast. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
The screenings should be conducted every other year, beginning at age 40 and continuing through age 74, according to the new recommendation.
Drs Mayer and Kalinsky provide insights and offer their impressions of the PADA-1 trial, focusing on ESR1 mutation monitoring with circulating tumor DNA (ctDNA).
Endocrine therapy, particularly when administered in combination with Verzenio (abemaciclib), is effective when compared with chemotherapy among patients with metastatic breast cancer who experienced disease progression on Ibrance (palbociclib), according to recently published research.
The AURKA inhibitor alisertib has emerged as an agent of particular note, demonstrating early signals of efficacy with a manageable safety profile for the treatment of patients with locally advanced or metastatic breast cancer whose disease is resistant to endocrine therapies.
With 5.6 months of additional follow-up and 78.3% of patients having completed Kisqali® (ribociclib) investigational treatment, the updated analysis shows...